Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Safety and Effectiveness of Rabeprazole for the Treatment of Gastroesophageal Reflux Disease (GERD) in Pediatric Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* History of at least 1 Gastroesophageal Reflux Disease (GERD) symptom within 3 months of screening~* Positive esophagogastroduodenoscopy~* Signed informed consent~* Female patients (if menstruating) must be practicing birth control~Exclusion Criteria:~* Patients with history of esophagitis~* Patients who have milk protein allergy~* Patients who have taken Proton Pump Inhibitors or H2-blockers within 3 days~* Patients who have taken sucralate or any medication that affects gastrointestinal motility~* Patients with H. pylori~* Patients with lab values outside the normal age appropriate range~* Patients who have participated in another trial within 30 days before screening~* Patients with allergies to Proton Pump Inhibitors

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: 11 Years
- Healthy Volunteers: f

Study Arms:
- Rabeprazole 0.5 mg/kg (Type: EXPERIMENTAL): rabeprazole 0.5mg/kg once daily for 12 weeks plus option for F/u another 24 weeks
- Rabeprazole 1.0 mg/kg (Type: EXPERIMENTAL): rabeprazole 1.0 mg/kg once daily for 12 weeks plus option for F/u another 24 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).